NCT04730050View on ClinicalTrials.gov

A Phase I Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetic Characteristics of TT-01025-CL in Healthy Subjects

PHASE1UnknownINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

February 17, 2021

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Healthy
Interventions
DRUG

TT-01025-CL

Oral tablet

Trial Locations (1)

89113

Las Vegas Clinical Research Unit, Las Vegas

Sponsors

Lead Sponsor

LG Chem
All Listed Sponsors
lead

LG Chem

INDUSTRY

NCT04730050 - A Phase I Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetic Characteristics of TT-01025-CL in Healthy Subjects | Biotech Hunter | Biotech Hunter